Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Cerro de Pasco Resources Advances Phase 2 Drilling at Quiulacocha Tailings Facility

Cerro de Pasco Resources Advances Phase 2 Drilling at Quiulacocha Tailings Facility

MT newswireMT newswire2026/11/03 13:54
09:54 AM EST, 11/03/2026 (MT Newswires) -- Cerro de Pasco Resources (CDPR.V) reported progress on the Phase 2 drilling campaign at the Quiulacocha tailings storage facility in Peru. As of Nov. 1, a total of 34 holes have been completed, for a total of 1,039 meters drilled, with 773 samples collected, the company said Tuesday. Drilling is expected to be completed in the second quarter of 2027. The Phase 2 campaign is expected to generate geological, geotechnical and environmental data for the first mineral resource estimate for the Quiulacocha tailings, targeted for the third quarter of 2027, and for the environmental impact assessment of the facility's reprocessing project.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss